understanding the barriers and challenges to successful integration of PDMPs in pharmacy 23 practice.
INTRODUCTION 25
In 2015, the Center for Disease Control and Prevention (CDC) reported that drug deaths 26 related to prescription opioids have remained stable since 2012. This may suggest that the 27 United States is gaining some ground in regards to fighting the epidemic of nonmedical use of 28 prescription drugs. However, there remains a significant amount of work to be done to improve 29 the prevention and treatment of substance abuse. 1 In 2007, the CDC reported that every 19 30 minutes someone dies from an unintentional prescription drug overdose in the United States, 31 which resulted in 27,000 deaths in 2007 alone. 2 If the number of deaths related to prescription 32 drug abuse is not alarming enough, the CDC reports that for every unintentional overdose, "9 33 persons are admitted for substance abuse treatment, 35 visit emergency departments, 161 report 34 drug abuse or dependence, and 461 report nonmedical uses of opioid analgesics". 2 Prescription 35 drug abuse is by no means a new problem in the United States. However, the continued growth 36 and the current scale of the problem has reason to raise serious concern. 3 The distribution of 37 opioid drugs has increased by over 7 times between 1997 and 2007. 2 Unfortunately, with this 38 increase in distribution of opioid drugs comes an increased risk of drug diversion. Drug 39 diversion occurs when prescription drugs are used for recreational purposes, and thus are 40 "diverted" from their original purpose. 4, 5 Although, drug diversion can occur at various stages 41 of the prescribing and dispensing process, the pharmacist may be the "last line of defense". 4, 5 42
Federal regulation 21 C.F.R. § 1306 requires that prescriptions for controlled substances 43 be issued for legitimate medical purposes by individual practitioners acting in the usual course of 44 their professional practice. 4, 5 That same law imposes responsibility on pharmacists who fill the 45 prescriptions. If pharmacists knowingly fill improper or invalid prescriptions, they, as well as the 46 prescribers, can be held accountable. 5, 6 Similarly, state law requires pharmacists performing 47 their duties to exercise professional judgment that is in the best interest of their patients ' health. 48 Before honoring prescriptions, pharmacists are required to take reasonable steps to determine 49 whether a prescription has been issued in compliance with state law. 4 According to federal 50 regulation 21 C.F.R. § 1306, a pharmacist may refuse to fill a prescription if professional 51 judgment suggests filling it would be contrary to law, be against the best interest of the patient, 52 aid or abet an addiction or habit, or be contrary to the health and safety of the patient. 4 53 Unfortunately, making a clinical decision to refuse to dispense a controlled substance may prove 54 difficult for many pharmacists due to a variety of factors that block or inhibit their ability to 55 make an evidence-based clinical decision such as lack of patient information or lack of evidence-56 based resources. 7 57
In recent decades, Prescription Drug Monitoring Programs (PDMPs) have become more 58 prominent across the United States. A PDMP is a statewide electronic database that collects 59 detailed data on controlled substance prescriptions (CSPs) in a state. 8, 9 As of 2013, 49 states 60 had enacted legislation to develop PDMPs, and 48 states have implemented these programs. 8 61 PDMPs can help identify major sources of prescription drug diversion such as prescription fraud, 62 forgeries, doctor shopping and improper prescribing and dispensing practices. 10 histories. An INSPECT report summarizes all CSPs a patient has been prescribed and includes 72 information regarding the practitioner(s) who prescribed the controlled substance as well as the 73 pharmacy and pharmacist who dispensed the CSP. 11 Although, a growing body of evidence 74 suggests that incorporation of PDMPs are effective in increasing clinical-decision making by 75 providing greater access to patient drug information, nearly 30% of providers in Indiana report 76 not using INSPECT, according to a 2012 study conducted by the Indiana University Center for 77
Health Policy (CHP). 10, 12 While Indiana pharmacists were significantly more likely to have 78 heard of INSPECT they, unfortunately, were not more likely to have reported using the program 79 in their pharmacy practice. 12 80
Pharmacists may be considered the "gatekeepers" of the controlled substances that have 81 had such an impact on the prescription drug abuse epidemic in the U.S. As the "last line of 82 defense," pharmacists are challenged with ensuring that patients being treated for legitimate 83 chronic pain have access to their CSPs, while identifying CSPs that have not been prescribed for 84 a valid medical purpose. 8 Furthermore, pharmacists have the responsibility to investigate the 85 validity of CSPs that raise red flags, resolve these red flags, and ultimately exercise their right to 86 refuse to dispense a CSP if the validity of the prescription cannot be verified. 87
PDMPs are valuable clinical resources that provide pharmacists with additional 88 information regarding their patients. This increased access to patient data facilitates pharmacists 89 ability to detect prescription drug abuse and diversion. 13 In a study conducted by Fleming et al., 90 pharmacists were prompted to use a PDMP in order to confirm suspicions of forgery related to 91
CSPs. 13 Another study examined variations in pharmacy practice between users and non-users of 92
PDMPs. This study suggested that PDMP users were less likely to discuss concerns of suspicion 93 of drug diversion with the patient, but were as likely to contact the provider, refer the patient 94 back to the provider, and refuse to fill the prescription. 14 The results from these two studies 95 suggest that utilization of PDMP data to investigate CSPs when there is a question to their 96 validity may increase a pharmacists level of confidence to take action and to exercise 97 corresponding responsibility. 13 98
The purpose of this study is to examine how integration and consistent use of a PDMP in 99 pharmacy practice impacts pharmacists' dispensing practices related to CSPs. The study aims to 100 determine if the use of INSPECT as a clinical resource in pharmacy practice: (1) promotes a 101 change in practice to dispense fewer CSPs, (2) increases the likelihood of a pharmacist to report 102 having refused to dispense a CSP, (3) and whether and to what extent more consistent use of 103 INSPECT influences a pharmacist's total annual refusals of CSPs. As more and more evidence 104 suggests that PDMPs are effective in reducing drug diversion and improving clinical decision-105 making, it is believed that pharmacists who report more consistent use of INSPECT in their 106 pharmacy practice will be more likely to refuse dispensation of CSPs as a result of increased 107 access to patient information that provides the data necessary to support their professional 108 judgment. 10 109
METHODS 110

Study Design 111
Survey & Data Collection 112
The study population included 10,606 providers who were identified by the IPLA as a and was calculated based on the number of years in professional practice. Pharmacists practicing 148 today were trained in one of three distinct cohorts, which are bound by events relating to the 149 adoption of the Doctorate of Pharmacy as the sole entry degree for the profession. The 150 parameters for training period are described in Table 2 . Training period was incorporated as a 151 covariate in all the statistical models for this study in order to control for variations in education 152 and training. 153
Data Analyses 154
All statistical analyses were performed using SAS Statistical Software 9.4 © . The 3 155 outcome variables were assessed with determination of odds ratio (OR) estimates and 95% Wald 156 confidence intervals (CIs). Descriptive statistics (frequencies, means, and standard deviations) 157
were performed when appropriate. Practice and demographic characteristics as well various 158 independent response variables were analyzed using independent samples t tests or one-way 159 analysis of variance (ANOVA). 160
Multiple Logistic Regression 161
In order to perform a binary logistic regression, the outcome measure dispensation 162 change was dichotomized into, 'dispensed fewer' or 'dispensed more', CSPs. The primary 163 independent variable of interest was whether or not respondents indicated that INSPECT was a 164 factor leading to their dispensation change. Backward elimination was used to fit the model and 165
to include all conceptually relevant independent variables in order to reduce possibility of a 166 suppressor effect within the model. 16 These variables were removed one by one and the 167 procedure determined the contribution of each variable at each step. All significant independent 168 variables identified through this process were retained in the multiple regression analysis. The 169 same process was followed for the other two (2) of Kolmogorov-Smirnov test for normality (D=.24, P<.01). As a result, these data were 178 analyzed using a multiple ordinal logistic regression model. 179
RESULTS 180
Demographics 181 The majority of respondents reported working in an outpatient setting (73.9%) compared 182 to an inpatient setting as reported in Table 3 . There were more male (54.4%) then female 183 respondents. The mean age of respondents was 46.9 years of age. The average years practicing 184 was 20.8 years with more than half the respondents having 20 or more years of experience. 185
Nearly all respondents reported having heard of INSPECT (94.3%) prior to receiving the survey. 186
However, only 71.8% of the respondents who had heard of INSPECT reported using it. 187
Change in Dispensation Practice of CSPs 188
A total of 506 (37.6%) respondents indicated that they had changed their dispensing 189 practice related to CSPs in the last 12 months. Of those who reported changing their dispensing 190 practices, significantly more respondents (74.7%) reported a change to dispense fewer CSPs (X 2 191 = 183.0, p < .0001) compared to those who reported a change to dispense more CSPs. 192 Respondents were also asked to report on the factors that led to the dispensation change. The 193 frequencies for the various factors leading to a dispensation change are provided in Table 4 . The 194 most frequently reported factors leading to a change in dispensing practice of CSPs were: 195
(1) New professional practice standards and protocols 196
(2) INSPECT providing greater access to patient prescription drug history As illustrated by these data, in table 4, more than half (53%) of pharmacists reporting a change in 199 their dispensing practice attribute the change to INSPECT increasing access to patient 200 prescription drug history. Pharmacists were 6.4 times more likely to report a dispensation 201 change to dispense fewer CSPs, if they also reported that increased access to patient prescription 202 drug history through INSPECT was a factor leading to the change (OR = 6.4, 95% CI, 3.437 -203 11.862). 204
Refused Dispensation of CSPs 205
Significant variations in pharmacists' decision to refuse to dispense a CSP existed within 206 several practice and demographic characteristics including pharmacy setting, gender, training 207 period, and use of INSPECT. These data are provided in Table 5 . Outpatient pharmacists were 208 21 times more likely to have refused to dispense a CSP compared to inpatient pharmacists (OR = 209 20.9, 95% CI, 11.007 -39.836). Practitioners who trained in Cohort 1 were 2.4 times more 210 likely to refuse to dispense a CSP compared to pharmacists trained in Cohort 3 (OR = 2.4, 95% 211 CI, 1.343 -4.218). In other words, pharmacists trained after full implementation of the 212 Accreditation Council for Pharmacy Education (ACPE) new accreditation and standards 213 guidelines were more confident in refusing dispensing a CSP. Also, male pharmacists were 2.5 214 times more likely to have reported refusing dispensation of a CSP in the past 12 months 215 compared to females (OR = 2.5, 95% CI, 1.454 -4.204). Multiple logistic regression analysis 216 indicated that pharmacists who reported using INSPECT were significantly more likely to have 217 refused dispensation of a CSP compared to practitioners who did not use INSPECT (OR = 2.2, 218 95% CI, 1.339 -3.693). 219
Annual Refusals of CSPs 220
Pharmacists may be more likely to refuse to dispense a CSP if using INSPECT, but the 221 study aimed to further examine the relationship between consistent use of INSPECT and the 222 magnitude of refusals reported by pharmacists. Table 6 provides visit" were statistically more likely to refuse to dispense more CSPs than pharmacists who 229 reported never checking INSPECT (ORperiodically = 3.0, 95% CI, 1.351 -6.763; OReveryvisit = 3.3, 230 95% CI, 1.307 -8.465). 231
DISCUSSION 232
Reducing prescription drug abuse in the United States is a multifaceted and intricate 233 process that must be addressed from multiple perspectives. One of the major driving forces 234 responsible for prescription drug abuse is the rise in opioid prescribing rates throughout the U.S. 235
The number of opioid prescriptions dispensed by retail pharmacies has increased consistently 236 since 1991. 17 General prescribing practices, high-volume prescribing, or even pill mills directly 237 influence the increasing rates of opioid prescriptions being dispensed by retail pharmacies. 17 238
Regardless of the original source of these prescriptions, pharmacists share responsibility with the 239 prescriber to ensure that these prescriptions are issued for a valid medical purpose. 240 DEA regulation 21 C.F.R. 1306.04 defines corresponding responsibility and understands 241 that pharmacists play an integral role in preventing the diversion of controlled substances. 6 242 Under this regulation, pharmacists are instructed to "exercise their professional judgment to 243 determine whether a prescription for a controlled substance was issued for a legitimate reason". 5 244 Unfortunately, pharmacists frequently find themselves in precarious situations where they must 245 determine if a controlled substance prescription was issued for a legitimate medical purpose by a 246 practitioner acting in the usual course of professional practice. Many times pharmacists in these 247 situations have few resources and have limited access to patient information needed to make 248 sound clinical-decisions. Maxwell et al., suggested that the limited access to patient information 249 fundamentally hampers pharmacists' abilities to make informed clinical-decisions. 18 250
The Department of Health and Human Services (DHHS) identified 'clinical practice 251 tools', such as PDMPs, as 1 of 8 primary domains necessary to preventing prescription drug 252 abuse. 17 PDMPs may alleviate, to some degree, pharmacists' lack of access to patient 253 information. One of the primary purposes of PDMPs is to increase access to patient prescription 254 drug histories, which are critical to making informed clinical-decisions and exercising good 255 professional judgment. According to the PDMP Center for Excellence, evidence continues to 256 suggest that PDMPs are valuable tools for providers that ultimately may improve clinical 257 decision-making and help reduce diversion of controlled substances. 10 258
This study set out to explore the use of Indiana's prescription drug monitoring program as 259 a support tool for improving clinical decision-making among pharmacists. It also examined the 260 influence PDMPs have on CSP dispensing behaviors. The results from this study suggest that the 261 use of INSPECT may lead to a reduction in CSP dispensing, which is illustrated by an increased 262 likelihood of pharmacists to modify their dispensing practice to dispense fewer CSPs as a result 263 of increased access to a patient's drug history. This also suggests that PDMPs may, in fact, 264 provide more information to pharmacists that may help to inform and support their professional 265 judgment to exercise corresponding responsibility. 266
Not only did the use of INSPECT result in a reported reduction of dispensed controlled 267 substances by pharmacists, but pharmacists were more likely to report refusing to dispense CSPs 268 if they used INSPECT. In this regard, our data suggest that the use of INSPECT may facilitate 269 pharmacists to exercise corresponding responsibility. We suspect that this is due to PDMPs 270 providing greater access to patient information that serves as evidence to support their 271 professional judgment to refuse to dispense a CSP in the event they are unable to resolve an 272 identified red flag while processing a prescription. 273
Additionally, more consistent use of INSPECT was significantly more likely to result in a 274 higher number of refusals to dispense controlled substances by a pharmacist. Practitioners who 275 reported using INSPECT periodically or at every visit were significantly more likely to refuse to 276 dispense a CSP as compared to pharmacists who reported never using INSPECT. This finding 277 further exemplifies the notion that the integration and consistent use of INSPECT in pharmacy 278 practice may provide pharmacists with the information necessary to be confident in their 279 professional judgment and clinical decisions. 280
The findings from this study are consistent with findings from previous studies which 281 concluded that PDMPs increase a pharmacist's level of confidence in their clinical decisions and 282 professional judgment. 13, 14 This study adds a unique dimension to the growing body of literature 283 surrounding prescription drug diversion and abuse, as the majority of current literature examines 284 the overall effectiveness of PDMPs and the role of prescribers in reducing drug diversion and 285 prescription drug abuse. 10 Less research is available regarding the impact PDMPs have on 286 pharmacists' dispensing practice relating to CSPs. This study was one of the first known studies 287 to quantify pharmacists' professional judgment to refuse to dispense a CSP by examining the 288 number of refusals reported by pharmacists. 289
Study Limitations 290
As PDMPs are now implemented in 49 states, there is a need for research that is capable 291 of evaluating their effectiveness in reducing drug diversion throughout the country. Many states 292 have started to evaluate these programs, but there are some limitations. The primary limitation 293 to this study was response bias. Issues of drug diversion and prescribing or dispensing practices 294 are considered to be controversial by many providers. Pharmacists may be hesitant to disclose 295 information regarding dispensing practices due to fear of legal ramifications. It is likely that 296 response bias may result in an overestimate of pharmacists reported number of refusals of CSPs. 297
However, the IPLA INSPECT Knowledge and Use Survey was administered as an anonymous 298 survey to help limit the potential response bias. Furthermore, the response rate for the survey 299 was low and may be a limitation to the study. However, measures were taken to compare 300
Indiana's pharmacist workforce to the study's sample in order to determine if the sample was 301 similar to that of Indiana's pharmacist workforce. Lastly, the study was conducted within one 302 state, Indiana. Therefore the generalizability of these findings to other states may be a limitation. 303
In light of these limitations, the study findings should still be considered due to their implications 304 and consistency with previous literature. 305
CONCLUSION 306
The Drug Enforcement Agency states that enforcement action against pharmacists is 307 most likely to occur when pharmacists fail to exercise corresponding responsibility. 5 308
Unfortunately, the interpretation of what constitutes "exercising corresponding responsibility" is, 309 to some degree, up for discussion. The DEA does indicate that pharmacists must identify and 310 resolve red flags prior to dispensing a controlled substance. Red flags arise as a result of pattern 311 prescribing, fraudulent prescriptions, paying cash, or geographic anomalies, to name a few. Yet, 312 lack of access to complete patient information as well as segmented relationships between 313 pharmacists and physicians make resolution of red flags a time consuming and tedious task. 314
These challenges may actually make exercising corresponding responsibility for pharmacists 315 quite difficult. However, this study suggests that pharmacists who consistently use prescription 316 drug monitoring programs in their pharmacy practice are over 3 times more likely to refuse 317 controlled substance prescriptions as compared to those pharmacists who do not use a PDMP as 318 a clinical practice tool. Implementing policies, strategies, and practices that support pharmacists 319 in fulfilling their duty to "exercise his/her independent judgment when determining whether a 320 prescription was issued for a legitimate medical purpose by a practitioner acting in the usual 321 course of professional practice" 5 , are vital to reducing diversion of prescription drugs. Future 322 research should focus on understanding the barriers and challenges to successful integration of 323 Table 4 Frequency of factors which led to a change in dispensing practice of controlled substance prescriptions What factors led you to change your dispensing practices? (N=497) N (%)
New professional practice standards and protocols 276 (56) INSPECT providing greater access to patient prescription drug history 263 (53) Increased professional awareness of risks, benefits, and other solutions 249 (50) Increased state or federal guidelines and recommendations 193 (39) Change in my patient mix 121 (24) I am afraid of legal ramifications 103 (21) Increased law enforcement activity 65 (13) Increased referrals from other physicians/providers for treatment of chronic pain patients 63 (13) Increased patient awareness of risks and benefits 38 (8) Increased referrals from other physicians/providers for treatment of acute (surgical/traumatic/short-term) pain patients 37 (7) Other 72 (15) 343 344 
